A Registry Called Every Child for Collecting Data and Biology Specimens on Younger Patients with Cancer
Tab Title Description
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Rochester, Minnesota: 15-008127
NCT ID: NCT02402244
Sponsor Protocol Number: APEC14B1
About this study
The purpose of this registry called Every Child, is to collect data and biospecimens from multiple body sources for younger patients with cancer over time. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.
- Enrollment can occur at any time after disease presentation including at time of disease progression or recurrence
- For patients who are to be enrolled on COG therapeutic studies, enrollment on APEC14B1 must occur prior to enrollment onto the therapeutic trial
- Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows
- All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant)
- All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
- Other benign/borderline conditions including
- Mesoblastic nephroma
- Myeloproliferative diseases including transient myeloproliferative disease
- Langerhan cell histiocytosis
- Lymphoproliferative diseases
- Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network (NCTN) ) therapeutic study, for whom there is a higher upper age limit
- All patients or their parents or legally authorized representatives must sign a written informed consent; parents will be asked to sign a separate consent for their own biospecimen submission
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
|Mayo Clinic Location
Mayo Clinic principal investigator
Carola Arndt, M.D.
Open for enrollment
Cancer Center Clinical Trials Referral Office
Publications are currently not available
Study Results Summary
Not yet available
Supplemental Study Information
Not yet available